Abstract. gastrin-releasing peptide receptor (grPr) is overexpressed by a variety of human tumors and in particular, identified to be upregulated in prostate cancers. the current study aimed to develop clinically translatable BBn analogue-based radioligands for positron emission tomography (Pet) of grPr-positive tumors. We developed radiolabeled BBn analogues and modified radiolabeled galacto-BBN analogues and then investigated their tumor-targeting efficacy in vivo. the chelator 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (noDaga) was used to radiolabel the peptides with 64 cu. the peptides were evaluated by measuring cell-based receptor-binding affinities. Biodistribution experiments and small animal imaging using Pet were performed in nude mice bearing subcutaneous Pc3 human prostate cancer xenografts. the conjugates were radiolabeled with yields >99%. the stability assay showed that 
Introduction
Prostate cancer is the second most frequently diagnosed cancer in men (914,000 new cases, 13.8% of the total), the fifth most common cancer across both genders, and the sixth leading cause of death from cancer in men in 2008 (1) . Hormone ablation therapy is a first-line treatment for prostate cancer; however, the duration of remission is limited and androgen-independent regrowth is observed in most patients (2) . additionally, most chemotherapeutic agents provide only a marginal benefit of survival or quality of life. therefore, the development of early diagnostic imaging agents and effective therapeutics for prostate cancer is important for prolongation of survival time and enhancement of patient quality of life.
Somatostatin and bombesin/gastrin-releasing peptide (BBn/grP) receptors are highly expressed in prostate cancers and can be selectively targeted by cytotoxic peptide conjugates. Peptide analogues are an exciting potential treatment for androgen-independent prostate cancer (3). BBn is a 14-amino-acid neuropeptide, first isolated from frog skin (4, 5) , and it has high affinity for the gastrin-releasing peptide receptor (grPr). BBn and its mammalian counterpart, grP, have similar biological properties and share nearly identical c-terminal amino acid sequences. in prostate cancer, grPr expression is closely associated with neoplastic transformation (6) , cell migration (7, 8) , proliferation (6, 9) , and invasion capacity (10, 11) .
grPr is an important target for radiolabeled BBn analogues that function as diagnostics or radionuclide therapies for grPr-positive tumors (12) . Various BBn analogues have been labeled with radiometals and suitable chelators and used for positron emission tomography (Pet) imaging in grPr-positive tumors (13) (14) (15) . 99m tc-labeled BBn analogues have been synthesized with diaminedithiol (DaDt) and the dithiadiphosphine framework (P 2 S 2 -cooH) as chelators. these analogues were evaluated in normal mice (16, 17) and Pc3 tumor-bearing mice, which represented a model of prostate cancer (18, 19 necessary for specific uptake into the tumors and to reduce uptake of radiometals into normal tissue. rogers et al labeled 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetic acid (Dota)-aoc is 8-aminooctanoic acid (aoc)-BBn(7-14) with 64 cu and then applied this radiotracer to a Pc3 xenograft model (20) . The tumor was well-visualized; however, sustained blood concentrations and persistent liver and kidney retention limited the potential clinical application of this tracer. Peptides as targeting molecules have unique characteristics in vivo including fast washout and excretion via the kidney because of their hydrophilic nature. to modulate the pharmacokinetic characteristics of radiolabeled peptide in vivo, researchers have tried to optimize to lower uptake in non-target organ and higher in target organ by modification of chelator and linker. Parry et al reported that shorter aliphatic linkers (from c4 to c12) between the Dota and BBn resulted in lower liver uptake with simultaneous higher uptake into grPr-positive breast tumors (21) . another group applied 1,4,7-triazacyclononane-1,4-diacetic acid (no2a) and various aliphatic linkers as a 1,4,7-triazacyclononane-1,4,7-triacetic acid (nota) derivative chelator and a pharmacokinetic modifier to BBN for 64 cu labeling to improve tumor uptake and pharmacokinetic properties, respectively. they reported that shorter and more hydrophilic linker produced superior small animal Pet images, with minimal accumulation in collateral tissue but the longer and more lipophilic linker resulted in high accumulation of radioactivity in liver and abdominal region (22) . Parry et al introduced short peptides as a linker between Dota and BBn to reduce retention of the tracer in the liver by activating the hepatobiliary pathway (23) . glycosylating the peptides is an alternative strategy to improve pharmacokinetic properties (24, 25 (24, 26, 27) , which can be used to target new vascularization in tumors, showed very similar kinetics in the kidney. in addition, rgD peptide conjugates displayed clearly reduced activity in the liver as well as increased uptake and retention in the tumor compared with the unmodified parent peptides.
64 cu is widely used because it is easy to produce with a medical cyclotron (28) . 64 cu can be used in Pet to evaluate the kinetics of protein or peptide interactions with target cells, and has a suitable positron energy (17.8%, e β + max =656 keV), and a β -emitter (39.6%, e β -max =573 keV) with a relatively long half-life (12.7 h) (29) .
in this study, we evaluated 64 cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (noDaga)-BBn and 64 cu-labeled noDaga-galacto-BBn in an in vitro receptor-binding assay and for in vivo tumor targeting by visualizing Pc3 prostate xenograft tumors with small animal Pet.
Materials and methods
Materials. all reagents were purchased from commercial sources and used as received without further purification. noDaga-BBn(7-14)nH 2 and noDaga-galacto-BBn(7-14) nH 2 High-performance liquid chromatography and mass spectrometry. the purity of noDaga-BBn(7-14)nH 2 and noDaga-galacto-BBn(7-14)nH 2 was analyzed using high-performance liquid chromatography (HPlc) (Shimadzu HPlc 10aVP system) with a c18 analytical column (5 µm, 3.0x150 mm). the elution conditions were as follows: a mixture of an aqueous solution of solvent A [0.1% trifluoroacetic acid (tfa) in acetonitrile] and B (0.1% tfa in water) with a 30-min linear gradient from 5 to 65% at a flow rate of 1 ml/min. Matrix-assisted laser desorption/ionization (MALDI) and MALDI time-of-flight (MALDI-TOF) experiments were performed on a Kratos Shimadzu axima-cfr.
Synthesis. Solid-phase peptide synthesis (SPPS) was performed on a Pit-Symphony Peptide Synthesizer using the 9-fluorenylmethoxycarbonyl (fmoc) methodology to produce the BBn(7-14)nH 2 peptide (22) . conjugation of noDaga to the BBn(7-14)nH 2 peptide resulted in noDaga-BBn(7-14)nH 2 via an active ester. a solution of noDaga (286 µmol) in dimethylformamide (DMf) (1 ml) and n,n-diisopropylethylamine (Diea) (2 M, 800 µl) was added on the resin with stirring at room temperature (rt). the stirring was continued for 12 h, after which the resin was washed three times with DMf. fmoc deprotection was performed in 20% piperidine; subsequently, the resin was washed three times with DMf. the noDaga-BBn(7-14)nH 2 was isolated by HPlc.
the preparation of noDaga-galacto-BBn(7-14)nH 2 was essentially similar to the preparation of noDaga-BBn(7-14) nH 2 described above. galacturonic acid was conjugated via an active ester onto the amine of glutamine (Q) on the BBn(7-14)nH 2 . to a mixture of galacturonic acid (10 µmol) in DMf (140 µl), hydroxybenzotriazole (HoBt) (2 M, 40 µl) and 1,3-diisopropylcarbodiimide (Dic) (2 M, 40 µl) were added on the resin with stirring at rt. the stirring was continued for 12 h, after which the resin was washed three times with DMf. fmoc deprotection was performed in 20% piperidine, and the resin was washed three times with DMf. a solution of noDaga (286 µmol) in DMf (1 ml) and Diea (2 M, 800 µl) was added to the resin with stirring at rt for 12 h. noDaga-galacto-BBn(7-14)nH 2 was isolated by HPlc. HPLC analysis and mass spectroscopy were used to confirm the identity of the product. 64 cu]noDaga-galacto-BBn in 3 ml of PBS (pH 7.4) was added to 4 ml of octanol. the mixture was then vigorously stirred for 5 min and centrifuged (3,000 rpm, 5 min). the activity of both the PBS and octanol phases was measured in the gamma counter, and logP values were calculated (n=3). 64 cu was used as a reference. the mobile phase consisted of 20 mM sodium acetate and 50 mM eDta (pH 5.0). itlc was performed using a radio-tlc scanner (aloka, tokyo, japan).
Internalization studies and in vitro stability

Pharmacokinetic study of [ 64 Cu]NODAGA-BBN and [
64 Cu] NODAGA-galacto-BBN. the care, maintenance, and treatment of animals in these studies followed protocols approved by the institutional animal care and use committee (iacuc) of the KiraMS (iacuc no. KiraMS 2013-80). female nude mice (BalB/cSlc-nu/nu, 6-weeks old) were purchased from japan Slc, inc. (Shizuoka, japan). animals were maintained in a temperature-controlled chamber at 22±3˚C with a 12-h light/dark cycle. relative humidity was maintained at 55±20%. Sterilized rodent diet and purified tap water were supplied ad libitum. animals were acclimatized to the condition described above for a week prior to use for the study. were transferred to polyethylene tubes. each radioactivity of them was counted by a scintillation counter. the radioactivity concentration of blood sample was expressed as the percentage of injected dose per a milliliter of blood (% iD/ml).
Pharmacokinetic parameters were estimated from the blood radioactivity concentration vs. time data by non-compartmental method using the non-linear least-squares regression program, Winnonlin ver. 2.0 (Pharsight corp., cary, nc, uSa).
Biodistribution studies. Male athymic nude (nu/nu) BalB/c mice (nara Biotech co., ltd., Seoul, Korea) were injected subcutaneously with 1x10 7 Pc3 human prostate cancer cells suspended in 100 µl of a Matrigel and PBS mixture (Matrigel:PBS = 1:1) at 6 weeks of age in the flank of the left thigh. the mice were subjected to biodistribution studies and Pet imaging when the tumor reached 0.7-0.9 cm in diameter (18-21 days after implantation).
the Pc3 tumor-bearing nude mice (n=3 for each group) were injected with ~1.48 MBq of [ 64 cu]noDaga-BBn or [ 64 Cu]NODAGA-galacto-BBN via the tail vein and sacrificed at 1 or 3 h after injection. the tumor and normal tissues of interest were removed and weighed, and their radioactivity levels were measured using a gamma counter. the uptake of radioactivity in the tumor and normal tissues was expressed as percent of injected dose per gram (% iD/g).
Small animal PET studies. Whole-body Pet images were obtained using a dedicated small animal Pet/ct scanner (inveon™; Siemens Preclinical Solutions, Malvern, PA, USA). animals were anesthetized with 1.5% isoflurane (Foran; choongwae Pharma co., Seoul, Korea) and injected with 11.1-18. cu] noDaga-galacto-BBn injection, then Pet images were acquired at 1 h after injection. Pet images were reconstructed using an ordered subset expectation maximization (oSeM) 2D algorithm with four iterations. regions of interest (rois) were drawn on the reconstructed images using inveon research Workplace (irW), provided by Siemens Preclinical Solutions.
Statistical analysis. Data were analyzed with graphPad Prism statistical software (graphPad Software, inc.). Student's two-tailed t-test was used to determine statistical significance at the 95% confidence level, with P<0.05 considered significantly different.
Results
Chemistry and radiochemistry. the noDaga-BBn(7-14) nH 2 conjugate was obtained with a 97.2% yield and a 19.2-min retention time (rt) on analytical HPlc. the MalDi-tof mass of noDaga-BBn(7-14)nH 2 was m/z=1298.3 (calculated for c 58 H 88 n 16 o 16 S 1 , 1297.5) (Table Ⅰ) .
the noDaga-galacto-BBn(7-14)nH 2 conjugate was obtained in 95.2% yield with a 19.8-min rt on analytical HPlc. the MalDi-tof mass of noDaga-galacto-BBn(7-14) nH 2 was m/z=1487.2 (calculated for c 65 H 99 n 17 o 21 S 1 , 1486.6) ( Table Ⅰ) . NODAGA-BBN and NODAGA-galacto-BBN were labeled with 64 Cu at 70˚C for 20 min. The final products of the noDaga-BBn and noDaga-galacto-BBn complexes are shown in fig. 1a . the radiolabeling yields of noDaga-BBn and noDaga-galacto-BBn were >99% (Table Ⅰ and fig. 1B ). 64 cu]noDaga-galacto-BBn, in terms of the percentage of the intact conjugate, was measured in human or mouse serum. no de-radiometallation or major degradation of the BBn tracer was detected after incubation with human and mouse sera at 37˚C for 1 h as monitored by radio-TLC. further investigation for clinical translation. additionally, 67 cu (t 1/2 =61 h) has favorable therapeutic β energy (100%, e β -max =577 keV, e γ =195 keV), and nearly equivalent to 64 cu in coordination chemistry. Moreover, the in vivo kinetics of 67 cu-labeled molecules can be predicted with 64 cu-labeled compounds (37) . thus, 67 cu-labeled BBn analogues may be utilized for radiotherapy of grPr-expressing tumors. in conclusion, noDaga-BBn and noDaga-galacto-BBn have been successfully prepared and radiolabeled with 64 cu. the radiolabeling procedures were simple and straightforward. Both [
64 cu]noDaga-BBn and [ 64 cu]noDaga-galacto-BBn stable against in vitro de-radiometallation and showed excellent in vivo tumor-targeting properties. in further studies, we will perform precise evaluation and characterization of these Pet probes in vitro and in vivo.
